TISSIUM

27 articles with TISSIUM

• 

  BioSpace Movers & Shakers, Dec. 18

  12/18/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• TISSIUM Receives FDA Investigational Device Exemption for Vascular Sealant

  11/17/2020

  TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has received approval from the U.S. Food and Drug Administration for its Investigational Device Exemption application for its vascular sealant. The approval is the most recent validation of TISSIUM’s efforts to de

• TISSIUM Secures €7M State Guaranteed Loan

  10/1/2020

  TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has secured a €7M state-guaranteed loan ( Prêt Garanti par l’Etat , or PGE). The loan was awarded by BNP Paribas, CM-CIC and bpifrance. Initiated by the French Government to support companies during the COVID-19 crisis, the PGE is a bank loan with a fixed interest rate ranging from 0.25% and 1.

• TISSIUM Receives CE Mark and Announces Manufacturing Compliance Certification from TÜV SÜD

  4/2/2020

  TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced the receipt of a CE-mark for its sterile biodegradable sealant in a pre-filled syringe.

• 

  BioSpace Global Roundup, March 5

  3/5/2020

  Life sciences companies from across the globe provide updates on their businesses and pipelines.
• 

  BioSpace Global Roundup, Feb. 13

  2/13/2020

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

• TISSIUM Receives Funding From the Crohn's & Colitis Foundation to Improve IBD Patient Outcomes

  2/11/2020

  Feb. 11, 2020 13:00 UTC PARIS--( BUSINESS WIRE )-- TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced today that they have received funding from the Crohn's & Colitis Foundation's IBD Ventures, a funding mechanism intended to accelerate the discovery and development of novel research-based products with the potential to alleviate suffering caused by inflammatory bowel disease (IBD). The funding will support T

• 

  BioSpace Global Roundup, Jan. 23

  1/23/2020

  Companies from across the globe provide updates on their businesses and pipelines.

• TISSIUM Recognized as a French Tech 120 Company

  1/21/2020

  TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced it has been named a French Tech 120 company.

• 

  BioSpace Global Roundup, Nov. 21

  11/21/2019

  Companies from across the globe provide updates on their businesses and pipelines.

• TISSIUM Closes €39M Series B Funding Round

  11/20/2019

  TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced it has raised €38.75 million in a Series B round of funding.

• TISSIUM Announces Publication in The Journal of Cardiovascular Surgery Detailing Preclinical and Clinical Evaluation of SETALIUMTM Vascular Sealant

  5/16/2019

  SETALIUMTM Vascular Sealant Shown to be Safe and Effective for Vascular Reconstruction

• Gecko Biomedical Rebrands as TISSIUM

  5/14/2019

  TISSIUM branding reflects broader focus on tissue reconstruction

• Tilak Announces CE Marking for Odysight, Its First Mobile Medical Game in Ophthalmology

  6/14/2018

  Tilak announced that Odysight, its first mobile medical game dedicated to the monitoring of patients with chronic eye diseases, has achieved CE marking.

• Gecko Biomedical Secures €6 Million in Funding under the Investments for the Future Programme (Programme d’investissements d’avenir, PIA), to Industrialize and Develop Innovative Solutions for Tissue Reconstruction

  1/24/2018

  This funding is a contribution towards the industrialization and development of innovative solutions in the area of tissue reconstruction, and the peripheral nerve in particular.

• Gecko Biomedical Builds Out Strategy For ‘Print On’ Polymers Platform

  12/7/2017

  Gecko’s proprietary technology platform is composed of fully synthetic light-activated polymers that can be ‘printed’ on living tissue inside and outside the body.

• Gecko Biomedical is Expanding Following Marketing Approval of its Vascular Sealant

  9/12/2017

• Gecko Biomedical Receives CE Mark Approval For SETALUM Sealant

  9/11/2017

• Gecko Biomedical Appoints Youssef Biadillah As Chief Development Officer. Maria Pereira Transitions To Chief Innovation Officer

  5/24/2017

• Gecko Biomedical Receives 1.4 Million Euros In Interest-Free Loan From Bpifrance To Advance Its Bio-Inspired Surgical Adhesive Solutions

  6/30/2016